| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Nuvalent, Inc. | 10%+ Owner | Class A Common Stock | 898K | $68.3M | $76.14 | Aug 2, 2021 | Direct |
| Verve Therapeutics, Inc. | 10%+ Owner | Common Stock | 2.5M | $25M | $10.00 | Jun 21, 2021 | Direct |
| Zenas BioPharma, Inc. | 10%+ Owner | Common Stock | 802K | $13.6M | $17.00 | Sep 16, 2024 | Direct |
| Acrivon Therapeutics, Inc. | 10%+ Owner | Common Stock | 888K | $3.86M | $4.35 | Nov 17, 2022 | Direct |
| Boundless Bio, Inc. | 10%+ Owner | Common Stock | 556K | Apr 2, 2024 | Direct | ||
| Artiva Biotherapeutics, Inc. | 10%+ Owner | Common Stock | 194K | Jul 22, 2024 | Direct | ||
| Acrivon Therapeutics, Inc. | 10%+ Owner | Series B Preferred Stock | 0 | Nov 17, 2022 | Direct | ||
| Artiva Biotherapeutics, Inc. | 10%+ Owner | Series B Preferred Stock | 0 | Jul 22, 2024 | Direct | ||
| Boundless Bio, Inc. | 10%+ Owner | Series B Preferred Stock | 0 | Apr 2, 2024 | Direct | ||
| Boundless Bio, Inc. | 10%+ Owner | Series C Preferred Stock | 0 | Apr 2, 2024 | Direct | ||
| Nuvalent, Inc. | 10%+ Owner | Series B Preferred Stock | 0 | Aug 2, 2021 | Direct | ||
| Verve Therapeutics, Inc. | 10%+ Owner | Series A-2 Preferred Stock | 0 | Jun 21, 2021 | Direct | ||
| Verve Therapeutics, Inc. | 10%+ Owner | Series B Preferred Stock | 0 | Jun 21, 2021 | Direct | ||
| Zenas BioPharma, Inc. | 10%+ Owner | Series A Convertible Preferred Stock | 0 | Sep 16, 2024 | Direct | ||
| Zenas BioPharma, Inc. | 10%+ Owner | Series B Convertible Preferred Stock | 0 | Sep 16, 2024 | Direct | ||
| Zenas BioPharma, Inc. | 10%+ Owner | Series C Convertible Preferred Stock | 0 | Sep 16, 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| ZBIO | Zenas BioPharma, Inc. | Sep 16, 2024 | 6 | $0 | 4 | Sep 18, 2024 | 10%+ Owner |
| ZBIO | Zenas BioPharma, Inc. | Sep 12, 2024 | 0 | $0 | 3 | Sep 12, 2024 | 10%+ Owner |
| ARTV | Artiva Biotherapeutics, Inc. | Jul 22, 2024 | 3 | $500K | 4 | Jul 22, 2024 | 10%+ Owner |
| ARTV | Artiva Biotherapeutics, Inc. | Jul 18, 2024 | 0 | $0 | 3 | Jul 18, 2024 | 10%+ Owner |
| BOLD | Boundless Bio, Inc. | Apr 2, 2024 | 4 | $0 | 4 | Apr 2, 2024 | 10%+ Owner |
| BOLD | Boundless Bio, Inc. | Mar 27, 2024 | 0 | $0 | 3 | Mar 27, 2024 | 10%+ Owner |
| ACRV | Acrivon Therapeutics, Inc. | Nov 17, 2022 | 2 | $0 | 4 | Nov 21, 2022 | 10%+ Owner |
| ACRV | Acrivon Therapeutics, Inc. | Nov 9, 2022 | 0 | $0 | 3 | Nov 9, 2022 | 10%+ Owner |
| NUVL | Nuvalent, Inc. | Aug 2, 2021 | 2 | $0 | 4 | Aug 3, 2021 | 10%+ Owner |
| NUVL | Nuvalent, Inc. | Jul 28, 2021 | 0 | $0 | 3 | Jul 28, 2021 | 10%+ Owner |
| VERV | Verve Therapeutics, Inc. | Jun 21, 2021 | 4 | $0 | 4 | Jun 22, 2021 | 10%+ Owner |
| VERV | Verve Therapeutics, Inc. | Jun 16, 2021 | 0 | $0 | 3 | Jun 16, 2021 | 10%+ Owner |